All In Biotech

Drug Trial Radar · NCT07371182

Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions

A Multi-center, Open-label, Single-arm Study of Luvometinib Monotherapy in Pediatric Langerhans Cell Histiocytosis With Single-system Special-site Single and Multifocal Bone Involvement

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
West China Second University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Langerhans cell histiocytosis (LCH) is the most common type of histiocytic disorder in children, affecting about 2.6 to 8.9 out of every million kids each year. It can look very different from one child to another-some cases get better on their own-but when it affects special bones (like the base of the skull, temporal bone, eye socket, or spine) or when there are multiple bone lesions in one system, children often face a higher risk of long-term complications and the disease coming back.Current guidelines in China and around the world recommend treating these children with whole-body therapy, usually a chemotherapy combination of vinblastine and prednisone. However, even with longer treatment courses, about 27.6% of children with multiple bone lesions still have the disease return, and less than 70% stay free of events after 5 years. Some even develop lasting nerve system problems. In recent years, researchers discovered that nearly all children with LCH have overactive MAPK signaling pathways in their cells. This discovery opened the door to using MAPK inhibitors as a new treatment. Studies have shown that these drugs work well and are safe for children with relapsed or hard-to-treat LCH. Even better, in some kids with single-system bone disease, the disease did not come back after stopping the drug-suggesting it might even cure certain cases. Luvometinib (also called FCN-159), a new MAPK inhibitor developed by Fosun Pharma in Shanghai, was approved in 2025 for treating adult LCH. A Phase II clinical study showed very encouraging results: 82.8% of patients saw their disease improve or disappear, and 74.4% stayed free of progression after 12 months. The drug was well tolerated, with side effects that were mild and manageable-no serious problems forced anyone to stop treatment.Compared to traditional chemotherapy, luvometinib has fewer and milder side effects, does not weaken the immune system, and lets children continue normal daily life and school. It is a simple oral pill taken once a day, so there's no need for intravenous lines or hospital stays, making treatment much easier and improving quality of life for both the child and the family.

Conditions

  • Langerhans Cell Histiocytosis (LCH)

Interventions

  • LuvometinibDrug

    5 mg/m² orally once daily for 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival rateTime frame: 2-year

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Children's Hospital

    Hefei, China · Recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • The Second Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Zunyi Medical University Affiliated Hospital, Guizhou Provincial Children's Hospital

    Zunyi, Guizhou, China · Recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Xi'an Children's Hospital

    Xi'an, Shaanxi, China · Recruiting

  • Xi'an Northwest Women's and Children's Hospital

    Xi'an, Shaanxi, China · Recruiting

  • West China Second Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Recruiting

  • Kunming Children's Hospital

    Kunming, Yunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.